Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02975336 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of M2951 in SLE
A Phase 2 study, sponsored by EMD Serono Research & Development Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 469
- Enrollment target
NCT02975336: Clinical Trial Phase 2 study, sponsored by EMD Serono Research & Development Institute.
NCT02975336 is a Phase 2 study that was terminated before completion, run by EMD Serono Research & Development Institute. The registered enrollment target is 469 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (253% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02975336, a Phase 2 study, was terminated before completion, sponsored by EMD Serono Research & Development Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 469 participants
- Enrollment target
Study Summary
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus (SLE).
Primary Outcome
SRI-4 response was defined as greater than or equal to (\>=) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score, no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA) and no treatment failure. SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence
Interventions
- DRUG Placebo
- DRUG M2951
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 469 participants |
| Start Date | 2017-01-04 |
| Est. Completion | 2020-03-23 |
| Phase | Phase 2 |
Why NCT02975336 stopped before completion
NCT02975336 is an interventional study that assigns participants to a tested intervention. The registered 469 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (253% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02975336 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02975336 about?
NCT02975336 is a clinical study titled "A Phase II Study of M2951 in SLE". M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus (SLE).
What is the current status of trial NCT02975336?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 469 participants. The study started on 2017-01-04. Estimated completion is 2020-03-23.
What interventions are being tested in trial NCT02975336?
The interventions under investigation include: Placebo (DRUG), M2951 (DRUG).
Who is sponsoring clinical trial NCT02975336?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02975336's enrollment target sits among peer trials
469 80th of 2000 higher than 1,921 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05256940 · 470 participants · NA
Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide
- NCT05458219 · 470 participants · Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- NCT05850689 · 470 participants · Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- NCT05935384 · 470 participants
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI